In Segment C, participants will get ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Contributors will acquire treatment until condition progression or maybe the members are unable to tolerate the study drugs. 88 These preclinical studies provide paradigms for foreseeable future clinical trials in AML, https://abbv-744-brd4-inhibitor-c31975.bloggip.com/32044839/considerations-to-know-about-is-abbv-744-effective-for-hematologic-cancers